Literature DB >> 18781309

[Localisation of bevacizumab in the monkey retina after an intravitreal injection of Avastin].

U Schraermeyer1, P Heiduschka, K U Bartz-Schmidt.   

Abstract

BACKGROUND: The aim was to investigate to what extent the vascular endothelial growth factor (VEGF) antibody bevacizumab is able to penetrate the retina in primates after an intravitreal injection of Avastin.
MATERIAL AND METHODS: Monkeys (Macaca fascicularis) were injected intravitreally with radioactively labelled and free Avastin. The animals were sacrificed 1, 4, 7, or 14 days after the injection, and the eyes were examined histologically and immunohistochemically. Blood samples were also taken on several days.
RESULTS: In the fundoscopic images, no pathologic changes could be found during the experiment. Using immunohistochemistry, bevacizumab was found in the choroid and the inner layers of the retina 1 day after the injection. Bevacizumab penetrated more quickly in the fovea than in the rest of the retina. It was also encountered in the photoreceptors and blood vessels. When (125)I-labelled Avastin was used, radioactivity could be determined in the blood serum 1 day after the injection.
CONCLUSION: The results show that the bevacizumab molecule can penetrate the retina after intravitreal injection of Avastin. However, there is an active uptake in the retinal cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18781309     DOI: 10.1007/s00347-008-1835-7

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  15 in total

1.  Effects of bevacizumab on retinal function in isolated vertebrate retina.

Authors:  M Lüke; M Warga; F Ziemssen; F Gelisken; S Grisanti; T Schneider; C Lüke; M Partsch; K U Bartz-Schmidt; P Szurman
Journal:  Br J Ophthalmol       Date:  2006-06-05       Impact factor: 4.638

2.  Safety of intravitreal injection of bevacizumab in rabbit eyes.

Authors:  Leonard Feiner; Emily E Barr; Ying-Bo Shui; Nancy M Holekamp; Milam A Brantley
Journal:  Retina       Date:  2006-10       Impact factor: 4.256

3.  Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy.

Authors:  Manish A Shah; David Ilson; David P Kelsen
Journal:  J Clin Oncol       Date:  2005-03-28       Impact factor: 44.544

4.  Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD.

Authors:  Marilita M Moschos; Dimitrios Brouzas; Michael Apostolopoulos; Chrysanthi Koutsandrea; Eleni Loukianou; Michael Moschos
Journal:  Doc Ophthalmol       Date:  2007-01-10       Impact factor: 2.379

5.  Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

Authors:  Jonathan Shahar; Robert L Avery; Gad Heilweil; Adiel Barak; Esther Zemel; Geoffrey P Lewis; Patrick T Johnson; Steven K Fisher; Ido Perlman; Anat Loewenstein
Journal:  Retina       Date:  2006-03       Impact factor: 4.256

6.  Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment.

Authors:  Raj K Maturi; Laura A Bleau; Donald L Wilson
Journal:  Retina       Date:  2006-03       Impact factor: 4.256

7.  Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes.

Authors:  Umit Ubeyt Inan; Berrin Avci; Tuncay Kusbeci; Berkant Kaderli; Remzi Avci; Sehime G Temel
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-04       Impact factor: 4.799

8.  Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.

Authors:  J Mordenti; R A Cuthbertson; N Ferrara; K Thomsen; L Berleau; V Licko; P C Allen; C R Valverde; Y G Meng; D T Fei; K M Fourre; A M Ryan
Journal:  Toxicol Pathol       Date:  1999 Sep-Oct       Impact factor: 1.902

9.  Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab.

Authors:  Swaantje Peters; Peter Heiduschka; Sylvie Julien; Focke Ziemssen; Heike Fietz; Karl Ulrich Bartz-Schmidt; Ulrich Schraermeyer
Journal:  Am J Ophthalmol       Date:  2007-04-23       Impact factor: 5.258

10.  Penetration of bevacizumab through the retina after intravitreal injection in the monkey.

Authors:  Peter Heiduschka; Heike Fietz; Sabine Hofmeister; Sigrid Schultheiss; Andreas F Mack; Swaantje Peters; Focke Ziemssen; Birgit Niggemann; Sylvie Julien; Karl Ulrich Bartz-Schmidt; Ulrich Schraermeyer
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-06       Impact factor: 4.799

View more
  2 in total

1.  Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients.

Authors:  Waheeda Rahman; Fred Kuanfu Chen; Jonathan Yeoh; Lyndon da Cruz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-11-17       Impact factor: 3.117

2.  [Spontaneous macula hemorrhage. Subhyaloid/sub-inner limiting membrane (ILM)].

Authors:  D Völcker; B Junker; L L Hansen
Journal:  Ophthalmologe       Date:  2012-07       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.